SMAD‑6, ‑7 and ‑9 are potential molecular biomarkers for the prognosis in human lung cancer
- Shuxian Pan
- Guangming Zhou
- Wentao Hu
- Hailong Pei
Affiliations: State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215123, P.R. China
- Published online on: July 9, 2020 https://doi.org/10.3892/ol.2020.11851
Copyright: © Pan
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
SMADs, a family of proteins that function as signal transducers and transcriptional regulators to regulate various signaling pathways, including the transforming growth factor‑β signaling pathway, are similar to the mothers against decapentaplegic family of genes and the sma gene family in Caenorhabditis elegans. SMADs generate context‑dependent modulation by interacting with various sequence‑specific transcription factors, such as E2F4/5, c‑Fos, GATA3, YY1 and SRF, which have been found to serve a key role in lung carcinoma oncogenesis and progression. However, the prognostic values of the eight SMADs in lung cancer have not been fully understood. In the present study, the expression levels and survival data of SMADs in patients with lung carcinoma from the Oncomine, Gene Expression Profiling Interactive Analysis, Kaplan‑Meier plotter and cBioPortal databases were downloaded and analyzed. It was found that the mRNA expression levels of SMAD‑6, ‑7 and ‑9 were decreased in lung adenocarcinoma and squamous cell carcinoma compared with that in adjacent normal tissues, while there was no significant difference in SMADs 1‑5. Survival analysis revealed that not only were low transcriptional levels of SMAD‑6, ‑7 and ‑9 associated with low overall survival but they also had prognostic role for progression‑free survival and post‑progression survival (P<0.05) in patients with lung carcinoma. In conclusion, the present study demonstrated that SMAD‑6, ‑7 and ‑9 are potential biomarkers for the prognosis of patients with lung carcinoma.